A more sensitive platform for the detection of low-abundance BRAF V600E mutations

Molecular and Cellular Biochemistry

Volumn 366, Issue 1-2, 2012, Pages 49-58

  Jiang, Weiqin ^a   Wang, Weibin ^a   Fu, Fangfang ^a   Teng, Xiaodong ^a   Wang, Haohao ^a   Wang, Haiyong ^a   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Allele specific real time PCR; BRAF; Pyrosequencing; Sanger sequencing

Indexed keywords

B RAF KINASE;

ACCURACY; ADULT; ALLELE; ARTICLE; CHINESE; COHORT ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PLASMID; PREVALENCE; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; THYROID PAPILLARY CARCINOMA;

ADULT; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LIMIT OF DETECTION; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLASMIDS; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; ROC CURVE; THYROID NEOPLASMS;

EID: 84862787115     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1282-2     Document Type: Article

References (31)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur AG, BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
2. Jo YS, Huang S, Kim YJ, Lee IS, Kim SS, Kim JR, Oh T, Moon Y, An S, Ro HK, Kim JM, Shong M (2009) Diagnostic value of pyrosequencing for the BRAFV600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf) 70:139-144
3. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792 (Pubitemid 40271173)
4. Xing J, Liu R, Xing M, Trink B (2011) The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun 404:958-962
5. Rousset B, Ziercher L, Borson-Chazot F (2011) Molecular analyses of thyroid tumors for diagnosis of malignancy on fine-needle aspiration biopsies and for prognosis of invasiveness on surgical specimens. Ann Endocrinol 72:125-128
6. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS (2011) Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 96:658-664
7. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45:818-821 (Pubitemid 39545368)
8. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R (2006) Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464 (Pubitemid 43886668)
9. Oler G, Cerutti JM (2009) High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115:972-980
10. Kim HS, Kim JO, Lee DH, Lee HC, Kim HJ, Kim JH, Jang YS, Lee JM, Kim SY, Kim YS (2011) Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma. Oncol Rep 25:1639-1644
11. Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471-478 (Pubitemid 44934704)
12. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH (2007) Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 9:464-471 (Pubitemid 47434113)
13. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790-799
14. Packham D, Ward RL, ApLin V, Hawkins NJ, Hitchins MP (2009) Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol 18:62-71
15. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589-595 (Pubitemid 40922263)
16. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G (2010) A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 29:132-138
17. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A (2011) Optimized allele-specific realtime PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn 13:23-28
18. DeLellis RA (2006) Pathology and genetics of thyroid carcinoma. J Surg Oncol 94:662-669
19. Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 949:2511-2516 (Pubitemid 34457134)
20. Pinzani P, Santucci C, Mancini I, Simi L, Salvianti F, Prates N, Massi D, Giorgi VD, Pazzagli M, lando C (2011) BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta. doi:10.1016/j.cca.2011.01.014
21. Yeo MK, Liang ZL, Oh T, Moon Y, An S, Kim MK, Kim KS, Shong M, Kim JM, Jo YS (2011) Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol (Oxf). doi:10.1111/j.1365-2265.2011.04115.x
22. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR, Lloyd RV (2006) BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Patho 15:136-143 (Pubitemid 44325474)
23. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262
24. Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, Moon WJ, Oh SY, Hwang TS (2008) Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17:118-125
25. Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, Lippi F, Grasso L, Basolo F, Bevilacqua G, Miccoli P, Di Coscio G, Vitti P, Pacini F, Pinchera A (2010) Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4,187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 95:1516-1527
26. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM (2010) Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 12:425-432
27. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH (2007) Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 9:464-471 (Pubitemid 47434113)
28. Huang MM, Arnheim N, Goodman MF (1992) Extension of base mispairs by Taq DNA polymerase: implications for single nucleotide discrimination in PCR. Nucleic Acids Res 20:4567-4573
29. Easterday WR, Van Ert MN, Zanecki S, Keim P (2005) Specific detection of Bacillus anthracis using a TaqMan mismatch amplification mutation assay. Biotechniques 38:731-735 (Pubitemid 40647042)
30. Soulie P, Poupon MF, Remvikos Y, Dutrillaux B, Muleris M (1999) Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers. Oncogene 18:775-781 (Pubitemid 29080335)
31. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867 (Pubitemid 38410730)